Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Hutchison China MediTech Ltd (HCM US)
Watchlist
36
Analysis
Health Care
•
Hong Kong
Hutchison China MediTech Ltd develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech markets its products globally.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Hutchison China MediTech Ltd
•
30 Oct 2023 10:31
Hutchmed China Ltd (13.HK/HCM.US) 23H1 - This Company Is Becoming More Attractive
We have seen over 35% share price rally after this insight was published. Obviously, the market is optimistic about the upcoming fruquintinib's FDA...
Xinyao (Criss) Wang
Follow
773 Views
Share
bullish
•
Thematic (Sector/Industry)
•
18 Mar 2024 08:55
Important New Policy for China’s Innovative Drugs – The Game Rule Is About to Change Radically
A new document about China's innovative drugs would change the game rule/outlook radically. We have reasons to start being optimistic that the...
Xinyao (Criss) Wang
Follow
290 Views
Share
bullish
•
Hutchmed China Ltd
•
20 Feb 2024 08:55
Hutchmed China Ltd (13.HK/HCM.US) - 2023 Results Preview and Catalysts in 2024
HUTCHMED has entered a harvest period.Product revenue would grow rapidly in the next two years, with promising catalysts head.Together with...
Xinyao (Criss) Wang
Follow
310 Views
Share
bullish
•
Hutchmed China Ltd
•
20 Dec 2023 08:55
Hutchmed China Ltd (13.HK/HCM.US) - A Valuable Option in the Portfolio
Despite market's lackluster response to fruquintinib’s FDA approval, we're optimistic about HUTCHMED’s outlook.Rich cash flow/future catalysts make...
Xinyao (Criss) Wang
Follow
433 Views
Share
bearish
•
Medlive Technology
•
10 Sep 2023 09:13
China Healthcare Weekly (Sep.8)- 9th VBP, Reliable Profit Model of Biotech, Medlive, China's Outlook
9th national VBP has begun. We analyzed the impact on companies. 23H1 reports make us realize even with negative policy, China Biotech can still...
Xinyao (Criss) Wang
Follow
407 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.31.1
x